CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: NICN1 (ImmuneEditome ID:84276)

1. Gene summary of enriched editing regions for NICN1

check button Gene summary
Gene informationGene symbol

NICN1

Gene ID

84276

GeneSynonyms-
GeneCytomap

3p21.31

GeneTypeprotein-coding
GeneDescriptionnicolin-1|NPCEDRG|PGs5|nicolin 1|tubulin polyglutamylase complex subunit 5
GeneModificationdate20230329
UniprotIDQ9BSH3;B4DX77
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr3:49423451-49424189:-ENST00000497742.5ENSG00000145029.10NICN1ncRNA_exonicAluSpchr3:49423451-49424189:-.alignment


Top

2. Tumor-specific enriched editing regions for NICN1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr3:49423451-49424189:-BRCAEER6.2605e-04image
ENSG00000145029.10,NICN1BRCAEAG9.5737e-03image
chr3:49423451-49424189:-COADEER2.1310e-02image
ENSG00000145029.10,NICN1COADEAG3.7075e-02image
chr3:49423451-49424189:-HNSCEER3.7871e-03image
ENSG00000145029.10,NICN1HNSCEAG1.4802e-02image
chr3:49423451-49424189:-KIRCEER8.0645e-10image
ENSG00000145029.10,NICN1KIRCEAG4.5876e-06image
chr3:49423451-49424189:-LUSCEER8.1971e-03image
ENSG00000145029.10,NICN1LUSCEAG3.5783e-02image
chr3:49423451-49424189:-THCAEER1.5768e-04image
ENSG00000145029.10,NICN1THCAEAG1.1087e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr3:49423451-49424189:-KIRCPathEER3.5292e-021.0057e-020.1189image
chr3:49423451-49424189:-LUSCPathEER1.7999e-021.8652e-030.1892image
ENSG00000145029.10,NICN1LUSCPathEAG4.6728e-033.8802e-040.2110image
ENSG00000145029.10,NICN1STADPathEAG2.9892e-042.8734e-040.2257image
chr3:49423451-49424189:-STADPathEER2.8320e-043.6416e-040.2228image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000145029.10,NICN1COADEAG4.6013e-021.1429e-022.9558e-02image

Top

3. Enriched editing regions and immune related genes for NICN1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr3:49423451-49424189:-DLBCEERENSG00000130024,PHF10-0.65168.5627e-033.1829e-04-0.5126imageNDHX9;EIF4A3;ELAVL1;HNRNPA1;IGF2BP2;IGF2BP3;NOP56;SRSF10;TARDBP;U2AF2NAT_cells_CD4_memory_restingGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr3:49423451-49424189:-DLBCEERENSG00000204371,EHMT2-0.61611.0654e-022.1880e-06-0.6402imageNEIF4A3;ELAVL1;HNRNPA1;IGF2BP2;IGF2BP3;NOP56;SRSF10;TARDBP;U2AF2EHMT2B_cells_naiveGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr3:49423451-49424189:-DLBCEERENSG00000163376,KBTBD8-0.59121.5511e-023.5355e-04-0.5092imageNELAVL1;IGF2BP2;IGF2BP3;NOP56;TARDBP;U2AF2NAMacrophages_M2GSVA_HALLMARK_G2M_CHECKPOINT
chr3:49423451-49424189:-DLBCEERENSG00000204366,ZBTB12-0.59791.8424e-021.1740e-04-0.5427imageNEIF4A3;ELAVL1;HNRNPA1;IGF2BP2;IGF2BP3;NOP56;SRSF10;U2AF2NAB_cells_naiveGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr3:49423451-49424189:-DLBCEERENSG00000100241,SBF1-0.57952.0770e-028.5965e-05-0.5516imageNDHX9;EIF4A3;ELAVL1;HNRNPA1;IGF2BP2;IGF2BP3;NOP56;TARDBP;U2AF2NAMacrophages_M2GSVA_HALLMARK_MITOTIC_SPINDLE
chr3:49423451-49424189:-DLBCEERENSG00000090006,LTBP4-0.58792.5703e-024.6639e-04-0.5003imageNDHX9;EIF4A3;ELAVL1;HNRNPA1;IGF2BP2;IGF2BP3;NOP56;TARDBP;U2AF2LTBP4Macrophages_M2GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr3:49423451-49424189:-DLBCEERENSG00000204463,BAG6-0.57012.5729e-021.2020e-06-0.6523imageNEIF4A3;ELAVL1;HNRNPA1;IGF2BP2;IGF2BP3;NOP56;SRSF10;TARDBP;U2AF2BAG6B_cells_naiveGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr3:49423451-49424189:-DLBCEERENSG00000170270,C14orf142-0.57032.5729e-022.0046e-03-0.4484imageNDHX9;EIF4A3;ELAVL1;IGF2BP2;IGF2BP3;NOP56;U2AF2NAMacrophages_M1GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr3:49423451-49424189:-DLBCEERENSG00000265806,MIR4292-0.56462.6334e-024.3138e-04-0.5028imageNNNAMacrophages_M2GSVA_HALLMARK_MITOTIC_SPINDLE
chr3:49423451-49424189:-DLBCEERENSG00000161036,LRWD1-0.56612.8784e-023.9520e-04-0.5057imageNDHX9;EIF4A3;ELAVL1;HNRNPA1;IGF2BP2;IGF2BP3;NOP56;TARDBP;U2AF2NAB_cells_naiveGSVA_HALLMARK_E2F_TARGETS

More results



Top

4. Enriched editing regions and immune related splicing for NICN1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr3:49423451-49424189:-
ESCAEERIRENSG00000119711.8chr1474064821:74064920:74065180:740653600.43459.0584e-031.0670e-050.4011imageNDHX9;EIF4A3;ELAVL1;HNRNPA1;IGF2BP2;IGF2BP3;NOP56;TARDBP;U2AF2ALDH6A1NK_cells_restingGSVA_HALLMARK_FATTY_ACID_METABOLISM
chr3:49423451-49424189:-
ESCAEERMEXENSG00000129657.10chr1777215831:77215844:77215870:77215883:77215896:77215984:77216101:772161140.32392.1747e-028.7702e-050.4171imageNDHX9;EIF4A3;ELAVL1;HNRNPA1;IGF2BP2;IGF2BP3;NOP56;SRSF10;TARDBP;U2AF2NAGSVA_HALLMARK_HEDGEHOG_SIGNALING
chr3:49423451-49424189:-
ESCAEERA3ENSG00000090975.8chr12122996457:122996577:122995388:122995490:122995388:122995660-0.34232.3165e-021.2907e-05-0.4250imageNDHX9;EIF4A3;ELAVL1;HNRNPA1;IGF2BP2;IGF2BP3;NOP56;SRSF10;TARDBP;U2AF2NAMacrophages_M0GSVA_HALLMARK_UV_RESPONSE_DN
chr3:49423451-49424189:-
KICHEERIRENSG00000173264.9chr1164286109:64286234:64286509:642867130.64812.7829e-027.5296e-080.6086imageNDHX9;EIF4A3;ELAVL1;HNRNPA1;IGF2BP2;IGF2BP3;NOP56;SRSF10;TARDBP;U2AF2NAT_cells_follicular_helperGSVA_HALLMARK_TGF_BETA_SIGNALING
ENSG00000145029.10,NICN1
KICHEAGIRENSG00000173264.9chr1164286109:64286234:64286509:642867130.64843.7901e-026.6514e-080.6106imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;MBNL1;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RBM27;RNF219;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NAT_cells_follicular_helperGSVA_HALLMARK_TGF_BETA_SIGNALING
ENSG00000145029.10,NICN1
PAADEAGIRENSG00000215910.3chr111787387:11788047:11788148:11788378-0.32872.3056e-022.7213e-07-0.4327imageNADAR;CPSF6;CSTF2T;DDX42;DGCR8;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FUS;GTF2F1;HNRNPA1;HNRNPK;HNRNPM;HNRNPU;IGF2BP2;ILF3;LSM11;NONO;NOP56;NOP58;PRPF8;RBFOX2;SLTM;SMNDC1;SND1;SRSF1;TAF15;TARDBP;TROVE2;U2AF2;UPF1;XRN2NAB_cells_naiveGSVA_HALLMARK_SPERMATOGENESIS
ENSG00000145029.10,NICN1
THYMEAGA3ENSG00000166579.11chr178460008:8460160:8466929:8467000:8463319:8467000-0.38582.5897e-031.7152e-06-0.4574imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;MBNL1;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RBM27;RNF219;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_E2F_TARGETS
ENSG00000145029.10,NICN1
THYMEAGA5ENSG00000015133.14chr1491283328:91283517:91289104:91289331:91285394:912893310.35225.1838e-039.0161e-070.4909imageNADAR;AIFM1;AUH;BCCIP;BUD13;CBX7;CELF2;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM22;RBM27;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZNF184NAMast_cells_restingGSVA_HALLMARK_G2M_CHECKPOINT
chr3:49423451-49424189:-
THYMEERIRENSG00000105369.5chr1941878989:41879175:41879534:41879653-0.35221.4057e-024.6182e-13-0.6548imageNEIF4A3;IGF2BP3CD79AMacrophages_M2GSVA_HALLMARK_G2M_CHECKPOINT
ENSG00000145029.10,NICN1
THYMEAGIRENSG00000197620.6chrX149540629:149540799:149542018:149542050-0.31502.7876e-025.3583e-05-0.4103imageNADAR;BCCIP;BUD13;CBX7;CSTF2T;DDX42;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPM;HNRNPU;IGF2BP2;IGF2BP3;LIN28;METTL3;MOV10;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;SMNDC1;SRSF1;SRSF3;TAF15;TRA2A;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184NAMast_cells_restingGSVA_HALLMARK_MTORC1_SIGNALING

More results



Top

5. Enriched editing regions and immune infiltration for NICN1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr3:49423451-49424189:-BLCAEERT_cells_CD4_naive2.9957e-04-0.2221image
ENSG00000145029.10,NICN1BLCAEAGT_cells_CD4_naive8.2271e-04-0.2035image
chr3:49423451-49424189:-BRCAEERB_cells_memory2.0052e-02-0.0747image
ENSG00000145029.10,NICN1BRCAEAGB_cells_naive1.0090e-02-0.0819image
chr3:49423451-49424189:-CESCEERT_cells_CD4_memory_resting2.4233e-02-0.1589image
ENSG00000145029.10,NICN1CESCEAGT_cells_CD4_memory_resting2.4104e-02-0.1567image
chr3:49423451-49424189:-DLBCEERMacrophages_M21.6543e-020.3555image
ENSG00000145029.10,NICN1DLBCEAGMacrophages_M21.6114e-020.3569image
chr3:49423451-49424189:-ESCAEERMast_cells_resting1.0295e-020.2394image
ENSG00000145029.10,NICN1ESCAEAGMast_cells_resting1.8756e-020.2134image
chr3:49423451-49424189:-GBMEERT_cells_CD89.3672e-030.2017image
ENSG00000145029.10,NICN1GBMEAGT_cells_CD81.0291e-020.1993image
chr3:49423451-49424189:-KIRCEERT_cells_CD4_memory_activated3.5369e-030.1562image
ENSG00000145029.10,NICN1KIRCEAGMonocytes2.6128e-02-0.1189image
chr3:49423451-49424189:-KIRPEERT_cells_follicular_helper1.5638e-040.2261image
ENSG00000145029.10,NICN1KIRPEAGT_cells_CD4_memory_resting2.7943e-03-0.1793image
chr3:49423451-49424189:-LGGEERMacrophages_M27.4467e-040.1463image
ENSG00000145029.10,NICN1LGGEAGMacrophages_M25.0174e-040.1509image
chr3:49423451-49424189:-LIHCEERDendritic_cells_resting4.7258e-03-0.1705image
ENSG00000145029.10,NICN1LIHCEAGDendritic_cells_resting3.1915e-03-0.1772image
ENSG00000145029.10,NICN1LUADEAGNeutrophils3.9790e-02-0.1017image
chr3:49423451-49424189:-LUSCEERT_cells_CD84.0903e-020.1245image
chr3:49423451-49424189:-MESOEERMonocytes4.5611e-020.2659image
ENSG00000145029.10,NICN1MESOEAGMonocytes1.8547e-020.3007image
chr3:49423451-49424189:-PAADEERT_cells_CD82.0647e-02-0.1927image
ENSG00000145029.10,NICN1PAADEAGT_cells_CD82.5911e-02-0.1850image
chr3:49423451-49424189:-PCPGEERMacrophages_M08.3060e-040.2844image
ENSG00000145029.10,NICN1PCPGEAGMacrophages_M01.1181e-030.2708image
chr3:49423451-49424189:-PRADEERNeutrophils4.0204e-02-0.0937image
ENSG00000145029.10,NICN1PRADEAGT_cells_CD83.3335e-020.0970image
chr3:49423451-49424189:-READEERB_cells_memory5.8080e-030.3610image
ENSG00000145029.10,NICN1READEAGB_cells_memory3.9761e-030.3726image
ENSG00000145029.10,NICN1SARCEAGPlasma_cells3.3362e-020.1578image
chr3:49423451-49424189:-SKCMEERMacrophages_M12.0924e-020.1116image
ENSG00000145029.10,NICN1SKCMEAGMast_cells_resting9.0963e-030.1257image
chr3:49423451-49424189:-STADEERMacrophages_M01.7086e-02-0.1484image
ENSG00000145029.10,NICN1STADEAGMacrophages_M03.4627e-02-0.1308image
chr3:49423451-49424189:-THCAEERT_cells_regulatory_(Tregs)3.9441e-040.1577image
ENSG00000145029.10,NICN1THCAEAGT_cells_regulatory_(Tregs)1.3736e-040.1695image
chr3:49423451-49424189:-THYMEERMacrophages_M11.4625e-040.3558image
ENSG00000145029.10,NICN1THYMEAGT_cells_regulatory_(Tregs)3.1395e-04-0.3373image
chr3:49423451-49424189:-UCSEERT_cells_CD82.3760e-020.3294image
ENSG00000145029.10,NICN1UCSEAGT_cells_CD82.2257e-020.3328image
chr3:49423451-49424189:-UVMEERT_cells_CD4_memory_resting2.9204e-03-0.3531image
ENSG00000145029.10,NICN1UVMEAGT_cells_CD4_memory_resting2.2404e-03-0.3620image


Top

6. Enriched editing regions and immune gene sets for NICN1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr3:49423451-49424189:-BLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER3.2787e-040.2207image
ENSG00000145029.10,NICN1BLCAGSVA_HALLMARK_UV_RESPONSE_UPEAG2.1214e-030.1873image
chr3:49423451-49424189:-BRCAGSVA_HALLMARK_GLYCOLYSISEER1.4829e-050.1386image
ENSG00000145029.10,NICN1BRCAGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG8.3472e-060.1414image
ENSG00000145029.10,NICN1CESCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.2317e-030.2231image
chr3:49423451-49424189:-CESCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.2661e-040.2509image
chr3:49423451-49424189:-CHOLGSVA_HALLMARK_MYC_TARGETS_V1EER1.9393e-030.5790image
ENSG00000145029.10,NICN1CHOLGSVA_HALLMARK_DNA_REPAIREAG1.7120e-030.5748image
ENSG00000145029.10,NICN1COADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG4.5885e-020.1617image
chr3:49423451-49424189:-DLBCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.2702e-02-0.3687image
ENSG00000145029.10,NICN1DLBCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG7.2391e-03-0.3950image
chr3:49423451-49424189:-ESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER2.0409e-030.2860image
ENSG00000145029.10,NICN1ESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG1.0809e-020.2310image
chr3:49423451-49424189:-GBMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER8.0428e-050.3021image
ENSG00000145029.10,NICN1GBMGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG9.1610e-050.2998image
ENSG00000145029.10,NICN1HNSCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG4.3823e-020.1438image
chr3:49423451-49424189:-KICHGSVA_HALLMARK_APICAL_SURFACEEER1.8338e-02-0.2918image
ENSG00000145029.10,NICN1KICHGSVA_HALLMARK_APICAL_SURFACEEAG1.5629e-02-0.2988image
ENSG00000145029.10,NICN1KIRCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG8.4738e-040.1776image
chr3:49423451-49424189:-KIRCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER2.4621e-050.2244image
chr3:49423451-49424189:-KIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.0403e-040.2222image
ENSG00000145029.10,NICN1KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.7220e-04-0.2175image
chr3:49423451-49424189:-LAMLGSVA_HALLMARK_ANDROGEN_RESPONSEEER3.2740e-020.2995image
ENSG00000145029.10,NICN1LAMLGSVA_HALLMARK_G2M_CHECKPOINTEAG4.0279e-020.2775image
ENSG00000145029.10,NICN1LGGGSVA_HALLMARK_SPERMATOGENESISEAG3.7571e-05-0.1784image
chr3:49423451-49424189:-LGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.0062e-060.2109image
ENSG00000145029.10,NICN1LIHCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG4.8989e-030.1692image
chr3:49423451-49424189:-LIHCGSVA_HALLMARK_FATTY_ACID_METABOLISMEER2.5537e-030.1819image
chr3:49423451-49424189:-LUADGSVA_HALLMARK_APOPTOSISEER9.2774e-050.1952image
ENSG00000145029.10,NICN1LUADGSVA_HALLMARK_APOPTOSISEAG1.5864e-040.1857image
ENSG00000145029.10,NICN1LUSCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG8.3977e-030.1575image
chr3:49423451-49424189:-LUSCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER3.2464e-030.1785image
chr3:49423451-49424189:-MESOGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.5103e-02-0.3204image
ENSG00000145029.10,NICN1MESOGSVA_HALLMARK_KRAS_SIGNALING_DNEAG4.8130e-02-0.2541image
ENSG00000145029.10,NICN1PAADGSVA_HALLMARK_UV_RESPONSE_DNEAG4.4304e-03-0.2350image
chr3:49423451-49424189:-PCPGGSVA_HALLMARK_MYC_TARGETS_V2EER1.1238e-02-0.2176image
ENSG00000145029.10,NICN1PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG7.2604e-04-0.1536image
chr3:49423451-49424189:-PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEER3.1121e-04-0.1639image
chr3:49423451-49424189:-READGSVA_HALLMARK_E2F_TARGETSEER1.7393e-02-0.3140image
ENSG00000145029.10,NICN1READGSVA_HALLMARK_DNA_REPAIREAG1.5331e-02-0.3170image
ENSG00000145029.10,NICN1SKCMGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.7172e-030.1508image
chr3:49423451-49424189:-SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.4867e-040.1762image
chr3:49423451-49424189:-STADGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER2.7727e-03-0.1856image
ENSG00000145029.10,NICN1STADGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG5.6461e-03-0.1709image
ENSG00000145029.10,NICN1TGCTGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG9.2521e-030.2744image
chr3:49423451-49424189:-TGCTGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.5484e-030.3421image
chr3:49423451-49424189:-THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.0937e-070.2294image
ENSG00000145029.10,NICN1THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG9.5562e-060.1963image
ENSG00000145029.10,NICN1THYMGSVA_HALLMARK_G2M_CHECKPOINTEAG1.2046e-06-0.4437image
chr3:49423451-49424189:-THYMGSVA_HALLMARK_E2F_TARGETSEER1.3525e-07-0.4792image
ENSG00000145029.10,NICN1UCECGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG4.2704e-020.1680image
chr3:49423451-49424189:-UCECGSVA_HALLMARK_HYPOXIAEER1.8936e-020.1940image
ENSG00000145029.10,NICN1UCSGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.2078e-030.4580image
chr3:49423451-49424189:-UCSGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.6675e-030.4462image
ENSG00000145029.10,NICN1UVMGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG4.5530e-020.2416image


Top

7. Enriched editing regions and drugs for NICN1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr3:49423451-49424189:-ACCAZD.2281EER2.4137e-02-0.3358image
ENSG00000145029.10,NICN1ACCAZD.2281EAG2.4958e-02-0.3340image
chr3:49423451-49424189:-BLCAAUY922EER3.0512e-03-0.1827image
ENSG00000145029.10,NICN1BLCABMS.536924EAG8.2509e-03-0.1614image
ENSG00000145029.10,NICN1BRCAA.770041EAG1.1443e-03-0.1036image
chr3:49423451-49424189:-BRCAATRAEER5.3287e-030.0896image
ENSG00000145029.10,NICN1CESCDasatinibEAG2.2139e-06-0.3228image
chr3:49423451-49424189:-CESCDasatinibEER1.0634e-06-0.3370image
ENSG00000145029.10,NICN1CHOLAKT.inhibitor.VIIIEAG4.5649e-030.5289image
chr3:49423451-49424189:-CHOLDMOGEER6.6722e-030.5184image
ENSG00000145029.10,NICN1COADGefitinibEAG1.6268e-03-0.2527image
chr3:49423451-49424189:-COADCCT018159EER2.4280e-03-0.2442image
chr3:49423451-49424189:-DLBCBMS.536924EER3.0084e-03-0.4325image
ENSG00000145029.10,NICN1DLBCBMS.536924EAG2.1349e-03-0.4460image
chr3:49423451-49424189:-ESCAAP.24534EER3.1995e-03-0.2738image
ENSG00000145029.10,NICN1ESCAKIN001.135EAG1.0908e-02-0.2307image
chr3:49423451-49424189:-GBMCGP.082996EER1.8050e-06-0.3618image
ENSG00000145029.10,NICN1GBMCGP.082996EAG2.4075e-06-0.3576image
ENSG00000145029.10,NICN1HNSCCyclopamineEAG2.8450e-03-0.2121image
chr3:49423451-49424189:-HNSCAZD6244EER8.0898e-03-0.1942image
ENSG00000145029.10,NICN1KICHATRAEAG4.2231e-04-0.4247image
chr3:49423451-49424189:-KICHATRAEER4.7931e-04-0.4210image
ENSG00000145029.10,NICN1KIRCCEP.701EAG1.0993e-08-0.2999image
chr3:49423451-49424189:-KIRCGDC.0449EER6.3689e-07-0.2639image
ENSG00000145029.10,NICN1KIRPBIBW2992EAG1.5054e-050.2573image
chr3:49423451-49424189:-KIRPBIBW2992EER1.9285e-060.2825image
chr3:49423451-49424189:-LAMLBX.795EER3.7107e-02-0.2927image
ENSG00000145029.10,NICN1LAMLBX.795EAG2.6952e-02-0.2983image
ENSG00000145029.10,NICN1LGGAS601245EAG8.5647e-09-0.2472image
chr3:49423451-49424189:-LGGAS601245EER1.9039e-10-0.2725image
chr3:49423451-49424189:-LIHCBleomycinEER2.2527e-020.1396image
ENSG00000145029.10,NICN1LIHCAG.014699EAG3.3546e-020.1309image
chr3:49423451-49424189:-LUADBMS.509744EER4.3518e-03-0.1430image
ENSG00000145029.10,NICN1LUADBMS.754807EAG2.4895e-03-0.1492image
chr3:49423451-49424189:-LUSCBMS.509744EER3.7924e-04-0.2148image
ENSG00000145029.10,NICN1LUSCAZD7762EAG2.2873e-04-0.2189image
ENSG00000145029.10,NICN1MESOEtoposideEAG1.3421e-020.3150image
ENSG00000145029.10,NICN1OVABT.263EAG4.1073e-020.1220image
chr3:49423451-49424189:-PAADGNF.2EER5.1715e-03-0.2343image
ENSG00000145029.10,NICN1PAADAZD6244EAG7.8299e-03-0.2200image
ENSG00000145029.10,NICN1PRADAZD6482EAG1.0081e-030.1496image
chr3:49423451-49424189:-PRADBicalutamideEER6.3430e-040.1554image
chr3:49423451-49424189:-READDMOGEER1.5570e-02-0.3190image
ENSG00000145029.10,NICN1READDMOGEAG1.9152e-02-0.3068image
ENSG00000145029.10,NICN1SARCBAY.61.3606EAG9.6998e-040.2426image
chr3:49423451-49424189:-SARCBAY.61.3606EER1.5182e-030.2334image
ENSG00000145029.10,NICN1SKCMEHT.1864EAG1.6995e-020.1150image
chr3:49423451-49424189:-SKCMEHT.1864EER1.5991e-020.1164image
chr3:49423451-49424189:-STADBMS.708163EER6.0035e-03-0.1706image
ENSG00000145029.10,NICN1STADBMS.708163EAG6.8160e-03-0.1671image
chr3:49423451-49424189:-TGCTGefitinibEER2.4085e-03-0.3288image
ENSG00000145029.10,NICN1TGCTAZ628EAG7.3367e-04-0.3514image
chr3:49423451-49424189:-THCACI.1040EER2.9234e-11-0.2914image
ENSG00000145029.10,NICN1THCACI.1040EAG3.4099e-10-0.2758image
chr3:49423451-49424189:-THYMBAY.61.3606EER4.3365e-110.5788image
ENSG00000145029.10,NICN1THYMBAY.61.3606EAG2.9813e-110.5805image
ENSG00000145029.10,NICN1UCECImatinibEAG1.4255e-020.2025image
chr3:49423451-49424189:-UCECMethotrexateEER1.9308e-020.1941image
chr3:49423451-49424189:-UCSCGP.60474EER6.6523e-03-0.3905image
ENSG00000145029.10,NICN1UCSCGP.60474EAG4.9985e-03-0.4028image
ENSG00000145029.10,NICN1UVMAP.24534EAG1.8991e-030.3674image
chr3:49423451-49424189:-UVMAP.24534EER9.5646e-040.3890image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType